NeoGenomics Stock Price Patterns
| NEO Stock | USD 8.27 0.03 0.36% |
Momentum
Impartial
Oversold | Overbought |
Quarterly Earnings Growth 1.306 | EPS Estimate Next Quarter 0.015 | EPS Estimate Current Year 0.1582 | EPS Estimate Next Year 0.3191 | Wall Street Target Price 14.8125 |
The hype-based summary links NeoGenomics attention patterns with price response and peers. Sentiment context for NeoGenomics is drawn from options positioning and short interest patterns.
NeoGenomics Short Interest Context
Short interest trends for NeoGenomics provide positioning context. The view summarizes short interest as a sentiment reference.
200 Day MA 9.2761 | Short Percent 0.0896 | Short Ratio 4.57 | Shares Short Prior Month 8.9 M | 50 Day MA 11.1226 |
Hype-to-Price Context for NeoGenomics
Average sentiment around NeoGenomics is summarized to provide attention context. Headline intensity is shown to frame short-term volatility context.
Sentiment alignment with price for NeoGenomics is shown as informational context. The summary provides attention context across different market periods.
NeoGenomics Implied Volatility | 1.12 |
Implied volatility for NeoGenomics provides a market-based measure of expected variability. The measure is presented as informational context for volatility interpretation.
Hype signals for NeoGenomics reflect how market attention changes over time and can be read with volatility context.
NeoGenomics after-hype prediction price | $ 8.27 |
Sentiment indicators are framed alongside forecasting, technical analysis, analyst estimates, and momentum.
Rule 16 for the current NeoGenomics contract
Rule 16 applies implied volatility to estimate a daily move of roughly 0.07% across the 2026-05-15 option cycle. The figure is a neutral volatility reference; near $ 8.27, it implies about $ 0.01 per day.
NeoGenomics | Build portfolio with NeoGenomics Stock |
Mean reversion in NeoGenomics' price occurs when temporary dislocations - caused by sentiment extremes, news events, or liquidity shocks - correct back toward the stock's historical fair value.
After-Hype Price Density Analysis
Understanding NeoGenomics' probability distribution helps investors calibrate position size to their risk tolerance. The tails of the NeoGenomics distribution capture low-probability but high-impact outcomes that naive point estimates ignore.
Next price density |
| Expected price to next headline |
Estimiated After-Hype Price Volatility
Using NeoGenomics' historical news impact data, we estimate the likely price corridor for the next trading session after a significant headline. NeoGenomics' after-hype downside and upside margins for the prediction period are 5.38 and 11.16, respectively. Note that past news reactions for NeoGenomics are not guaranteed to repeat, particularly in novel market environments.
Current Value
The after-hype framework applied to NeoGenomics assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. NeoGenomics is Stable at this time.
Price Outlook Analysis
Have you ever been surprised when a price of a Company such as NeoGenomics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading NeoGenomics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with NeoGenomics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.52 | 2.89 | 0.09 | 0.01 | 10 Events | 8 Events | In 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
8.27 | 8.27 | 0.00 |
|
Hype Timeline
On the 17th of March 2026 NeoGenomics is traded for 8.27. The company has historical hype elasticity of 0.09, and average elasticity to hype of competition of 0.01. NeoGenomics is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is now at -0.52%. %. The volatility of related hype on NeoGenomics is about 15210.53%, with the expected price after the next announcement by competition of 8.28. About 99.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.28. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. NeoGenomics has Price/Earnings To Growth (PEG) ratio of 2.09. The company recorded a loss per share of 0.84. The firm had not issued any dividends in recent years. NeoGenomics completed a 1:100 stock split on 16th of April 2003. Considering the 90-day investment horizon the next forecasted press release will be in 10 days. NeoGenomics Basic Forecasting Models can be used to cross-verify projections for NeoGenomics. The model set adds a statistical reference.Related Hype Analysis
Understanding how NeoGenomics' direct competitors react to news events helps investors anticipate contagion effects and sector-wide sentiment shifts that may affect NeoGenomics's performance.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| XGN | Exagen Inc | -0.01 | 6 per month | 0.00 | -0.29 | 4.28 | -6.15 | 18.81 | |
| MDXH | MDxHealth SA ADR | -0.19 | 7 per month | 2.77 | 0.02 | 5.31 | -4.23 | 17.05 | |
| STXS | Stereotaxis | 0.11 | 22 per month | 0.00 | -0.09 | 4.69 | -6.01 | 14.48 | |
| ACRS | Aclaris Therapeutics | -0.08 | 8 per month | 4.49 | 0.07 | 6.27 | -7.99 | 84.20 | |
| QTRX | Quanterix Corp | 0.02 | 6 per month | 0.00 | -0.12 | 6.84 | -7.27 | 34.06 | |
| SGMT | Sagimet Biosciences Series | 0.02 | 23 per month | 0.00 | -0.04 | 5.78 | -7.32 | 22.02 | |
| SMTI | Sanara Medtech | 0.02 | 4 per month | 0.00 | -0.08 | 5.60 | -4.67 | 14.97 | |
| ARCT | Arcturus Therapeutics Holdings | 0.36 | 9 per month | 0.00 | -0.06 | 6.13 | -5.23 | 17.23 | |
| HUMA | Humacyte | -0.02 | 9 per month | 4.78 | 0.01 | 11.11 | -8.11 | 43.72 | |
| TKNO | Alpha Teknova | -0.04 | 7 per month | 0.00 | -0.12 | 7.89 | -7.75 | 23.17 |
NeoGenomics Additional Predictive Modules
Forecasting NeoGenomics's price movement relies on structured analysis of indicator behavior, momentum signatures, and historical volatility patterns. Model confidence should be calibrated against recent prediction accuracy for NeoGenomics, not just historical fit.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Sentiment Indicators & Methodology
Sentiment analysis for NeoGenomics evaluates news tone, positioning, and narrative momentum. Positioning shifts can amplify volatility changes during regime transitions. NeoGenomics has a market cap of 1.07 B, P/E of 272.37, ROE of -12.43%.
This section for NeoGenomics is built from periodic company reporting and market reference feeds, with harmonization applied to align reporting definitions. Values may update on different source schedules.
This content is curated and reviewed by:
Raphi Shpitalnik - Junior Member of Macroaxis Editorial BoardPair Trading with NeoGenomics
A pair strategy built around NeoGenomics is useful when investors want to reduce directional market exposure while still expressing a relative-value idea. A disciplined pair strategy still requires monitoring because correlation can weaken when market regimes change.
Moving together with NeoGenomics Stock
Moving against NeoGenomics Stock
| 0.9 | ATEX | Anterix | PairCorr |
| 0.85 | RWAYL | MSCI ACWI exAUCONSUMER | PairCorr |
| 0.85 | TTE | TotalEnergies SE ADR | PairCorr |
| 0.85 | RCI | Rogers Communications | PairCorr |
| 0.82 | HCA | HCA Holdings | PairCorr |
| 0.81 | REMRF | Red Moon Resources | PairCorr |
Using correlated positions as NeoGenomics substitutes during tax-loss harvesting allows investors to capture a tax benefit without disrupting portfolio allocation. The key is finding instruments that track NeoGenomics closely enough to maintain equivalent risk and return.
The correlation of NeoGenomics with other assets is a key diversification metric. Pairing NeoGenomics with uncorrelated or negatively correlated instruments can reduce overall portfolio volatility without necessarily reducing expected returns.
Correlation analysis and pair trading evaluation for NeoGenomics can be used to frame hedging context. This approach is commonly reviewed within sectors and across broader groups.